Pancreatic Cancer Research

ResearcherUniversity of MiamiActive in the last 2 years

Peter J. Hosein

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8537-6397; OpenAlex author ID A5065012486. Sources: ClinicalTrials.gov.

Their work

Papers
37 (first author 6, last author 4)
Trials
2 (principal investigator on 2)
Grants
1
Labs led
1
Collaborators
182
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 3 papers · 2019: 3 papers · 2020: none · 2021: 1 paper · 2022: 3 papers · 2023: 5 papers, 1 trial · 2024: 2 papers · 2025: 4 papers · 2026: 7 papers, 1 grant · 2027: 1 trial

Papers 37

  1. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  2. Optimization of first-line treatment selection in advanced pancreatic adenocarcinoma using artificial intelligence. Co-author DOI 10.1038/s41698-026-01543-6↗
  3. IL1RAP-expressing myeloid-stromal networks represent a therapeutic vulnerability to improve chemoimmunotherapy sensitivity in pancreatic cancer. Co-author DOI 10.1172/jci.insight.202487↗
  4. Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18664-0↗
  5. ASO Visual Abstract: Factors Driving Attrition from Neoadjuvant Therapy to Pancreatectomy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18846-w↗
  6. Leveraging the perioperative window in pancreatic cancer: lessons from the PROSPER trial. Co-author DOI 10.21037/gs-2026-0166↗
  7. Cost-Effectiveness of Daraxonrasib vs Chemotherapy in Previously Treated Metastatic Pancreatic Adenocarcinoma Co-author DOI 10.64898/2026.09.16.26363246↗
  8. Intersection of Black race and carbohydrate antigen 19-9 nonproduction underpins worse pathologic response to neoadjuvant therapy in pancreatic cancer. Co-author DOI 10.1002/cncr.70130↗
  9. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  10. Impact of new onset diabetes on pancreatic cancer outcomes. First author DOI 10.21037/jgo-2025-217↗
  11. The Interplay Between DNA Repair and the Immune Microenvironment in Pancreatic Cancer. First author DOI 10.3390/biomedicines13051031↗
  12. Transmembrane TNF-TNFR2 signaling as a critical immunoregulatory node in pancreatic cancer. Co-author DOI 10.1080/2162402x.2024.2326694↗
  13. Improving patient stratification and selection for curative-intent treatment in localized pancreatic cancer. Co-author DOI 10.21037/hbsn-23-668↗
  14. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  15. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
  16. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer. Co-author DOI 10.1200/po.23.00152↗
  17. Texture Analysis Identifies Distinct Radiomic Signals Associated with Survival in Hispanic Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13013-x↗
  18. Detection and therapeutic implications of homologous recombination repair deficiency in pancreatic cancer: a narrative review. First author DOI 10.21037/jgo-23-85↗
  19. Distinct mechanisms of innate and adaptive immune regulation underlie poor oncologic outcomes associated with KRAS-TP53 co-alteration in pancreatic cancer. Co-author DOI 10.1038/s41388-022-02368-w↗
  20. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overco… Co-author DOI 10.1053/j.gastro.2022.07.076↗
  21. Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy resp… Co-author DOI 10.7554/elife.78921↗
  22. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic ad… Co-author DOI 10.1186/s12885-021-08474-4↗
  23. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  24. Does Neoadjuvant Chemotherapy Change the Role of Regional Lymphadenectomy in Pancreatic Cancer Survival? Co-author DOI 10.1097/mpa.0000000000001339↗
  25. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer. Last author DOI 10.21037/jgo.2019.09.12↗
  26. The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. First author DOI 10.21037/jgo.2017.10.12↗
  27. Exceptional response to FOLFIRINOX in a patient with pancreatic cancer and a germline RAD51C mutation. Last author DOI 10.21037/jgo.2018.03.11↗
  28. Neoadjuvant Nab-paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible f… Last author DOI 10.21873/anticanres.12692↗
  29. Effect of complications on oncologic outcomes after pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.jss.2017.02.036↗
  30. Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. First author DOI 10.1016/j.jvir.2016.10.023↗
  31. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. Co-author DOI 10.1002/jso.24314↗
  32. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Co-author DOI 10.1016/s1470-2045(16)00172-8↗
  33. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Last author DOI 10.1016/j.pan.2015.08.010↗
  34. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage I… Co-author DOI 10.1016/j.pan.2014.07.003↗
  35. A phase II trial of nab-Paclitaxel as second-line therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1097/coc.0b013e3182436e8c↗
  36. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma. First author DOI 10.1016/j.jvir.2012.09.012↗
  37. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. Co-author DOI 10.1186/1471-2407-12-199↗

Trials 2

  1. Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency Principal investigator NCT07565155↗
  2. Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma Principal investigator NCT05440942↗

Grants 1

  1. Catalyst Research Award (Precision Promise biospecimens and data): Peter Hosein AWARD pancan:2026-peter-hosein-catalyst-research-award-precision-promis

Closest collaborators

The 25 strongest of 182 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jashodeep Datta · 10 shared papers, 2022–2026 · strength 2.23
  2. Nipun B. Merchant · 11 shared papers, 2019–2026 · strength 2.10
  3. Erin M. Dickey · 6 shared papers, 2024–2026 · strength 1.50
  4. Caitlin A. Hester · 4 shared papers, 2024–2026 · strength 1.00
  5. Mary P Martos · 4 shared papers, 2024–2026 · strength 1.00
  6. Gretel Terrero · 3 shared papers, 2026 · strength 0.94
  7. Haleh Amirian · 3 shared papers, 2024–2026 · strength 0.72
  8. Casey P. Borowsky · 1 shared paper, 2025 · strength 0.54
  9. Anna Bianchi · 2 shared papers, 2024–2026 · strength 0.50
  10. Tanios Bekaii‐Saab · 3 shared papers, 2019–2026 · strength 0.49
  11. Jashodeep Datta · 2 shared papers, 2024–2025 · strength 0.44
  12. Harshabad Singh · 2 shared papers, 2026 · strength 0.44
  13. Forrest Bethel · 1 shared paper, 2026 · strength 0.43
  14. Gilberto De Lima Lopes Jr. · 2 shared papers, 2013–2026 · strength 0.42
  15. Heng Tan · 1 shared paper, 2023 · strength 0.39
  16. Sunwoo Han · 1 shared paper, 2026 · strength 0.39
  17. David B. Spetzler · 2 shared papers, 2023–2026 · strength 0.39
  18. Iago De Castro Silva · 3 shared papers, 2022 · strength 0.39
  19. Siddharth Mehra · 3 shared papers, 2022 · strength 0.39
  20. Feyruz Virgilia Rassool · 1 shared paper, 2025 · strength 0.37
  21. Yixing Jiang · 1 shared paper, 2025 · strength 0.37
  22. Aaron Ciner · 1 shared paper, 2025 · strength 0.37
  23. David A. Kooby · 2 shared papers, 2023–2025 · strength 0.35
  24. Daniel Erik Abbott · 2 shared papers, 2023–2025 · strength 0.35
  25. Shishir Kumar Maithel · 2 shared papers, 2023–2025 · strength 0.35

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.